Data / Drug companies / Sucralfate
Sucralfate: 39 companies and 63 products in the FDA NDC directory
Sucralfate is listed in the FDA National Drug Code Directory by 39 companies, with 63 products in commercial distribution. 52 of the products (82.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; suspension, and the newest product started marketing on July 16, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 39
- Products
- 63
- Generic (ANDA) products
- 52 (82.5%)
- Application numbers
- 12
- Routes
- Oral
- Brand names
- Carafate
- openFDA record search
- api.fda.gov
Companies that list sucralfate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Advanced Rx of Tennessee, LLC | 4 | tablet | Generic drugs (ANDA) | March 13, 2023 |
| A-S Medication Solutions | 3 | tablet | Generic drugs (ANDA) | May 20, 2023 |
| Bryant Ranch Prepack | 3 | tablet | Generic drugs (ANDA) | February 17, 2020 |
| Bryant Ranch Prepack | 3 | tablet | Generic drugs (ANDA) | May 20, 2023 |
| Cardinal Health 107, LLC | 3 | tablet; suspension | Generic drugs (ANDA) | July 10, 2026 |
| NuCare Pharmaceuticals,Inc. | 3 | tablet | Generic drugs (ANDA) | May 20, 2023 |
| Preferred Pharmaceuticals Inc. | 3 | tablet | Generic drugs (ANDA) | December 10, 2024 |
| Allergan, Inc. | 2 | tablet; suspension | New drug applications (NDA) | December 16, 1993 |
| Aphena Pharma Solutions - Tennessee, LLC | 2 | tablet | Generic drugs (ANDA) | February 17, 2020 |
| Bryant Ranch Prepack | 2 | tablet; suspension | Generic drugs (ANDA) | July 10, 2024 |
| Chartwell RX, LLC | 2 | suspension; tablet | Generic drugs (ANDA) | April 14, 2025 |
| Direct_Rx | 2 | tablet | Generic drugs (ANDA) | March 2, 2023 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 2 | tablet | Generic drugs (ANDA) | May 20, 2023 |
| Northwind Health Company, LLC | 2 | tablet | Generic drugs (ANDA) | November 18, 2020 |
| Proficient Rx LP | 2 | tablet | Generic drugs (ANDA) | February 17, 2020 |
| Safecor Health, LLC | 2 | tablet; suspension | Generic drugs (ANDA) | July 16, 2026 |
| American Health Packaging | 1 | suspension | Generic drugs (ANDA) | August 1, 2023 |
| Amneal Pharmaceuticals NY LLC | 1 | tablet | Generic drugs (ANDA) | April 22, 2022 |
| Amneal Pharmaceuticals NY LLC | 1 | tablet | Generic drugs (ANDA) | March 2, 2024 |
| Asclemed USA Inc. | 1 | tablet | Generic drugs (ANDA) | November 11, 1996 |
| Atlantic Biologicals Corp. | 1 | suspension | Generic drugs (ANDA) | March 15, 2022 |
| AvKARE | 1 | tablet | Generic drugs (ANDA) | October 31, 2023 |
| Chartwell Governmental & Specialty RX, LLC. | 1 | suspension | Generic drugs (ANDA) | April 14, 2025 |
| Cosette Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | December 19, 2024 |
| Coupler LLC | 1 | tablet | Generic drugs (ANDA) | February 4, 2025 |
| Glenmark Pharmaceuticals Inc., USA | 1 | suspension | Generic drugs (ANDA) | January 5, 2026 |
| Kesin Pharma Corporation | 1 | suspension | Generic drugs (ANDA) | July 1, 2024 |
| Mylan Institutional Inc. | 1 | tablet | Generic drugs (ANDA) | September 24, 2013 |
| Mylan Pharmaceuticals Inc. | 1 | tablet | Authorized generics (NDA) | September 25, 2017 |
| Pacific Pharma, Inc. | 1 | suspension | Authorized generics (NDA) | February 1, 2024 |
| Pai Holdings, LLC DBA Pai Pharma | 1 | suspension | Generic drugs (ANDA) | March 15, 2022 |
| Redpharm Drug | 1 | tablet | Generic drugs (ANDA) | May 20, 2023 |
| Richmond Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | November 21, 2024 |
| Strides Pharma Science Limited | 1 | suspension | Generic drugs (ANDA) | July 10, 2024 |
| Teva Pharmaceuticals USA, Inc. | 1 | tablet | Generic drugs (ANDA) | November 11, 1996 |
| Torrent Pharmaceuticals Limited | 1 | suspension | Generic drugs (ANDA) | September 15, 2025 |
| Viona Pharmaceuticals Inc | 1 | tablet | Generic drugs (ANDA) | May 20, 2023 |
| VistaPharm, LLC | 1 | suspension | Generic drugs (ANDA) | March 15, 2022 |
| Zydus Lifesciences Limited | 1 | tablet | Generic drugs (ANDA) | May 20, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 46 | 73% |
| Suspension | 17 | 27% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 52 | 82.5% |
| Authorized generics (NDA) | 9 | 14.3% |
| New drug applications (NDA) | 2 | 3.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Aluminum Complex | 63 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.